Pfiz­er’s Covid sto­ry — and rev­enue spree — con­tin­ue with $54B vac­cine and pill in spot­light again

Covid, Covid and more Covid news and ques­tion­ing dom­i­nat­ed Pfiz­er’s fi­nan­cial call with in­vestors on Tues­day — and of course, its top line rev­enue.

Pfiz­er re­port­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER